News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
239,782 Results
Type
Article (7396)
Company Profile (18)
Press Release (232367)
Multimedia
Podcasts (8)
Webinars (2)
Section
Business (63203)
Career Advice (301)
Deals (14787)
Drug Delivery (32)
Drug Development (36870)
Employer Resources (24)
FDA (6474)
Job Trends (4921)
News (122050)
Policy (11685)
Tag
2027 Genetown Elite (1)
2027 Genetown Standard (1)
2027 Pharm Country Elite (1)
Academia (572)
Accelerated approval (15)
Adcomms (8)
Allergies (68)
Alliances (14842)
ALS (68)
Alzheimer's disease (722)
Antibody-drug conjugate (ADC) (150)
Approvals (6735)
Artificial intelligence (199)
Autoimmune disease (77)
Automation (10)
Bankruptcy (147)
Best Places to Work (4607)
BIOSECURE Act (2)
Biosimilars (64)
Biotechnology (18)
Bladder cancer (115)
Brain cancer (35)
Breast cancer (279)
Cancer (2663)
Cardiovascular disease (172)
Career advice (270)
Career pathing (6)
CAR-T (180)
CDC (10)
Celiac Disease (1)
Cell therapy (409)
Cervical cancer (23)
Clinical research (33460)
Collaboration (640)
Compensation (205)
Complete response letters (20)
COVID-19 (786)
CRISPR (36)
C-suite (299)
Cystic fibrosis (67)
Data (3858)
Denatured (4)
Depression (59)
Diabetes (191)
Diagnostics (2362)
Digital health (12)
Diversity (4)
Diversity, equity & inclusion (9)
Drug discovery (87)
Drug pricing (60)
Drug shortages (19)
Duchenne muscular dystrophy (112)
Earnings (35503)
Editorial (20)
Employer branding (1)
Employer resources (19)
Events (33240)
Executive appointments (346)
FDA (8325)
Fibrodysplasia Ossificans Progressiva (4)
Friedreich's ataxia (6)
Frontotemporal dementia (14)
Funding (570)
Gene editing (88)
Generative AI (18)
Gene therapy (259)
GLP-1 (279)
Government (1307)
Grass and pollen (2)
Guidances (288)
Healthcare (6151)
HIV (33)
Huntington's disease (15)
IgA nephropathy (55)
Immunology and inflammation (82)
Immuno-oncology (25)
Indications (64)
Infectious disease (902)
Inflammatory bowel disease (87)
Inflation Reduction Act (6)
Influenza (52)
Intellectual property (159)
Interviews (46)
IPO (8108)
IRA (20)
Job creations (572)
Job search strategy (221)
JPM (11)
Kidney cancer (12)
Labor market (15)
Layoffs (51)
Leadership (6)
Legal (2113)
Liver cancer (51)
Longevity (3)
Lung cancer (349)
Lymphoma (227)
Machine learning (17)
Management (7)
Manufacturing (286)
MASH (97)
Medical device (4765)
Medtech (4789)
Mergers & acquisitions (7331)
Metabolic disorders (500)
Multiple sclerosis (84)
NASH (8)
Neurodegenerative disease (115)
Neuropsychiatric disorders (33)
Neuroscience (1259)
NextGen: Class of 2026 (1505)
Non-profit (717)
Obesity (206)
Opinion (106)
Ovarian cancer (112)
Pain (95)
Pancreatic cancer (147)
Parkinson's disease (122)
Partnered (11)
Patents (299)
Patient recruitment (296)
Peanut (19)
People (15155)
Pharmaceutical (8)
Pharmacy benefit managers (9)
Phase 1 (10744)
Phase 2 (14738)
Phase 3 (10994)
Pipeline (3239)
Policy (73)
Postmarket research (796)
Preclinical (3938)
Press Release (9)
Prostate cancer (128)
Psychedelics (13)
Radiopharmaceuticals (131)
Rare diseases (391)
Real estate (1015)
Recruiting (7)
Regulatory (10369)
Reports (16)
Research institute (534)
Resumes & cover letters (39)
Rett syndrome (22)
RNA editing (5)
RSV (30)
Schizophrenia (74)
Series A (86)
Series B (78)
Service/supplier (2)
Sickle cell disease (48)
Special edition (2)
Spinal muscular atrophy (34)
Sponsored (17)
Startups (683)
Stomach cancer (6)
Supply chain (39)
Tariffs (12)
The Weekly (3)
Vaccines (291)
Venture capital (18)
Weight loss (109)
Women's health (26)
Worklife (5)
Date
Last 7 days (285)
Last 30 days (1033)
Last 365 days (15009)
2026 (1386)
2025 (15061)
2024 (16922)
2023 (19100)
2022 (22240)
2021 (23633)
2020 (21796)
2019 (14439)
2018 (10637)
2017 (11473)
2016 (9554)
2015 (11737)
2014 (8102)
2013 (5878)
2012 (6040)
2011 (6749)
2010 (6216)
Location
Africa (182)
Alabama (28)
Alaska (2)
Arizona (77)
Arkansas (3)
Asia (18319)
Australia (5019)
California (5675)
Canada (1852)
China (552)
Colorado (221)
Connecticut (299)
Delaware (131)
Europe (29644)
Florida (869)
Georgia (118)
Hawaii (1)
Idaho (7)
Illinois (370)
India (52)
Indiana (202)
Japan (223)
Kansas (23)
Kentucky (10)
Louisiana (11)
Maine (44)
Maryland (634)
Massachusetts (3855)
Michigan (97)
Minnesota (193)
Missouri (63)
Montana (12)
Nebraska (8)
Nevada (79)
New Hampshire (45)
New Jersey (1804)
New Mexico (4)
New York (1667)
North Carolina (608)
North Dakota (2)
Northern California (2803)
Ohio (118)
Oklahoma (2)
Oregon (9)
Pennsylvania (1121)
Puerto Rico (11)
Rhode Island (11)
South America (304)
South Carolina (42)
Southern California (2257)
Tennessee (68)
Texas (877)
United States (19609)
Utah (131)
Virginia (135)
Washington D.C. (21)
Washington State (527)
West Virginia (2)
Wisconsin (25)
Wyoming (1)
239,782 Results for "imugene limited".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Imugene Announces Outstanding Response Rates from the Phase 1b Trial of the Azer-cel Allogeneic CAR T in 3L+ DLBCL
July 14, 2025
·
8 min read
Business
Imugene and Kincell Bio Announce Strategic Manufacturing and Process Development Partnership
Imugene, Ltd. and Kincell Bio, LLC, announce a strategic manufacturing and process development partnership, which includes the sale of Imugene’s North Carolina Current Good Manufacturing Practice manufacturing facility and the transfer of process and analytical development activities to Kincell.
April 16, 2024
·
5 min read
Bile Tract Cancer expansion study opens following clearance of Imugene’s MAST trial high dose cohort
Imugene Limited (ASX: IMU), a clinical stage immuno-oncology company, is pleased to announce that enrolment has opened for its expansion study in bile tract cancer (cholangiocarcinoma) patients, having completed the fifth, high dose cohort in the intratumoural (IT) arm of the monotherapy dose escalation study evaluating its cancer-killing virus CF33-hNIS (VAXINIA).
April 15, 2024
·
5 min read
Imugene Highlights Recent Achievements and Looks Ahead to Key Upcoming Immuno-oncology Catalysts
Imugene Limited, a clinical stage immuno-oncology company, highlighted recent progress across the company’s immuno-oncology portfolio and provided an update on anticipated upcoming milestones.
February 22, 2024
·
8 min read
BioCapital
MaxCyte Signs Strategic Platform License with Imugene to Advance their Cancer Immunotherapy Programs
MaxCyte, Inc. and Imugene announced the signing of a strategic platform license.
January 23, 2024
·
5 min read
Imugene’s CF33-hNIS (VAXINIA) & MAST Study Featured at ASCO GI Cancers Symposium
Imugene Limited (ASX:IMU), a clinical stage immuno-oncology company, is pleased to announce further details from its poster presentation at the ASCO Gastrointestinal Cancers Symposium (ASCO-GI) currently being conducted in San Francisco.
January 18, 2024
·
3 min read
Imugene’s oncolytic virotherapy VAXINIA and B cell immunotherapy HER-Vaxx featured at the AACR Annual Meeting 2024
Imugene Limited (ASX: IMU), a clinical stage immuno-oncology company, is pleased to announce poster presentations featuring its CF33 oncolytic virotherapy VAXINIA and B cell immunotherapy HER-Vaxx at the American Association for Cancer Research (AACR) Annual Meeting 5-10 April 2024, in San Diego, CA.
April 9, 2024
·
6 min read
Press Releases
AABB To Run Limited-Time Certified Advanced Biotherapies Professional (CABP) Free Exam Retake Offer
December 1, 2025
·
1 min read
Press Releases
Haemonetics Acquires Vivasure Medical Limited
January 9, 2026
·
5 min read
BioCapital
NeoImmuneTech and Imugene enter into strategic research collaboration to improve cancer treatments
Imugene Ltd and NeoImmuneTech, Inc. announced a strategic collaboration to evaluate Imugene’s allogeneic CAR T, azer-cel, in combination with NIT’s proprietary immune T cell amplifier “Fc-fused recombinant human interleukin-7", NT-I7, for the treatment of cancer.
December 11, 2023
·
5 min read
1 of 23,979
Next
